Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/17717| Title: | Glioma Through the Looking GLASS: Molecular Evolution of Diffuse Gliomas and the Glioma Longitudinal AnalySiS Consortium. | Austin Authors: | Aldape, Kenneth;Amin, Samirkumar B;Ashley, David M;Barnholtz-Sloan, Jill S;Bates, Amanda J;Beroukhim, Rameen;Bock, Christoph;Brat, Daniel J;Claus, Elizabeth B;Costello, Joseph F;de Groot, John F;Finocchiaro, Gaetano;French, Pim J;Gan, Hui K ;Griffith, Brent;Herold-Mende, Christel C;Horbinski, Craig;Iavarone, Antonio;Kalkanis, Steven N;Karabatsou, Konstantina;Kim, Hoon;Kouwenhoven, Mathilde C M;McDonald, Kerrie L;Miletic, Hrvoje;Nam, Do-Hyun;Ng, Ho Keung;Niclou, Simone P;Noushmehr, Houtan;Ormond, Ryan;Poisson, Laila M;Reifenberger, Guido;Roncaroli, Federico;Sa, Jason K;Sillevis Smitt, Peter A E;Smits, Marion;Souza, Camila F;Tabatabai, Ghazaleh;Van Meir, Erwin G;Verhaak, Roel G W;Watts, Colin;Wesseling, Pieter;Woehrer, Adelheid;Yung, W K Alfred;Jungk, Christine;Hau, Ann-Christin;van Dyck, Eric;Westerman, Bart A;Yin, Julia;Abiola, Olajide;Zeps, Nikolaj;Grimmond, Sean;Buckland, Michael;Khasraw, Mustafa;Sulman, Erik P;Muscat, Andrea M;Stead, Lucy | Affiliation: | Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, ON, Canada Jackson Laboratory for Genomic Medicine, Ten Discovery Drive, Farmington, CT, USA Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC, USA Case Comprehensive Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA National Brain Tumor Society, Newton, MA, USA Departments of Medical Oncology and Cancer Biology, Dana-Farber Cancer Institute, Boston, MA, USA CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA Yale School of Public Health, New Haven, CT, and Department of Neurosurgery, Brigham and Women's Hospital, Boston, MA, USA University of California San Francisco, San Francisco, CA, USA University of Texas, MD, and Anderson Cancer Center, Houston, TX, USA Fondazione IRCCS Istituto Neurologico Besta, Milano, Italy Department of Neurology, Erasmus MC, Rotterdam, The Netherlands Olivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australia Department of Radiology, Henry Ford Health System, Detroit, MI, USA Division of Experimental Neurosurgery, Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany Department of Neurology, Department of Pathology, Institute for Cancer Genetics, Columbia University Medical Center, New York, USA Department of Neurosurgery, Henry Ford Health System, Detroit, MI, USA Salford Royal Hospital, Stott Lane, Greater Manchester, UK Department of Neurology, VU University Medical Center/Brain Tumor Center, Amsterdam, The Netherlands Cure Brain Cancer Biomarkers and Translational Research Group, Prince of Wales Clinical School, University of NSW, Sydney, Australia Department of Pathology, Haukeland University Hospital, Bergen, Norway Department of Neurosurgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea Department of Pathology, Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong Luxembourg Institute of Health, NorLux Neuro-Oncology Laboratory, Luxembourg Department of Neurosurgery, University of Colorado School of Medicine, Aurora, CO, USA Department of Neuropathology, Heinrich Heine University Duesseldorf Medical Faculty, Duesseldorf, Germany Division of Neuroscience and Experimental Psychology, Faculty of Biology, Medicine and Health, University of Manchester, UK Research Institute for Future Medicine, Samsung Medical Center, Seoul, Korea Department of Neurology, Erasmus Medical Center, Rotterdam, The Netherlands Department of Radiology and Nuclear Medicine, Erasmus Medical Center, Rotterdam, The Netherlands Interdisciplinary Division of Neuro-Oncology, Departments of Neurology and Neurosurgery, University Hospital, Tübingen, Germany Departments of Neurosurgery, Hematology, and Medical Oncology, School of Medicine, and Winship Cancer Institute, Emory University, Atlanta, GA, USA Department of Clinical Neurosciences, Division of Neurosurgery, University of Cambridge, UK Department of Pathology, VU University Medical Center/Brain Tumor Center Amsterdam, Amsterdam, The Netherlands Institute of Neurology, Medical University of Vienna, Vienna, Austria Anderson Cancer Center, Houston, TX, USA Department of Neurosurgery, University of Heidelberg, Heidelberg, Germany Brain Tumor Center Amsterdam, Cancer Center Amsterdam, VU Medical Center, Amsterdam, The Netherlands Cure Brain Cancer Biomarkers and Translational Research Group, Prince of Wales Clinical School, University of NSW, Australia Monash University and Epworth Health, Melbourne, Victoria, Australia University of Melbourne and Victorian Comprehensive Cancer Centre, Melbourne, Victoria, Australia Royal Prince Alfred Hospital and University of Sydney, NSW, Australia University of Sydney, NSW, Australia University of Texas MD Anderson Cancer Center, Houston, TX, USA Deakin University, Geelong, Victoria, Australia St James's University Hospital, Leeds, UK Princess Máxima Center for Pediatric Oncology and University Medical Center Utrecht, The Netherlands |
Issue Date: | 8-Feb-2018 | Date: | 2018-02-08 | Publication information: | Neuro-oncology 2018; online first: 8 February | Abstract: | Adult diffuse gliomas are a diverse group of brain neoplasms that inflict a high emotional toll on patients and their families. The Cancer Genome Atlas (TCGA) and similar projects have provided a comprehensive understanding of the somatic alterations and molecular subtypes of glioma at diagnosis. However, gliomas undergo significant cellular and molecular evolution during disease progression. We review the current knowledge on the genomic and epigenetic abnormalities in primary tumors and after disease recurrence, highlight the gaps in the literature, and elaborate on the need for a new multi-institutional effort to bridge these knowledge gaps and how the Glioma Longitudinal AnalySiS Consortium (GLASS) aims to systemically catalog the longitudinal changes in gliomas. The GLASS initiative will provide essential insights into the evolution of glioma toward a lethal phenotype, with the potential to reveal targetable vulnerabilities, and ultimately, improved outcomes for a patient population in need. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/17717 | DOI: | 10.1093/neuonc/noy020 | Journal: | Neuro-oncology | PubMed URL: | 29432615 | Type: | Journal Article | Subjects: | characterization evolution glioma sequencing subtypes |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.